Evidence map›Paper›PMID 40716972›Full record

ArticleClinical lung cancer2025

Brief Report: Central Nervous System Metastases After Chemoradiation Followed by Durvalumab for Unresectable Locally Advanced Nonsmall Cell Lung Cancer.

John Sharp, Philip Young, Songzhu Zhao, Lai Wei, Sandip H Patel, Mingjia Li, Jeremy Brownstein, Karl Haglund, Joshua Palmer, Raju Raval and 12 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical lung cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

John SharpDivision of Medical Oncology, The Ohio State University, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH. Electronic address: john.sharp@osumc.edu.
Philip YoungDivision of Hematology and Oncology, Kaiser Permanente Tacoma Medical Center, Tacoma, WA.
Songzhu ZhaoDivision of Medical Oncology, The Ohio State University, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH.
Lai WeiDivision of Medical Oncology, The Ohio State University, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH.
Sandip H PatelDivision of Hematology/Oncology, Adena Health System, Adena Cancer Center, Chillicothe, OH.
Mingjia LiDivision of Medical Oncology, The Ohio State University, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH.
Jeremy BrownsteinDivision of Radiation Oncology, The Ohio State University, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH.
Karl HaglundDivision of Radiation Oncology, The Ohio State University, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH.
Joshua PalmerDivision of Radiation Oncology, The Ohio State University, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH.
Raju RavalDivision of Radiation Oncology, The Ohio State University, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH.
Sasha BeyerDivision of Radiation Oncology, The Ohio State University, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH.
Logan RoofDivision of Medical Oncology, The Ohio State University, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH.
Peter ShieldsDivision of Medical Oncology, The Ohio State University, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH.
Kai HeDivision of Medical Oncology, The Ohio State University, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH.
Jacob KaufmanDivision of Medical Oncology, The Ohio State University, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH.
Regan M MemmottDivision of Medical Oncology, The Ohio State University, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH.
Asrar AlahmadiDivision of Medical Oncology, The Ohio State University, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH.
David P CarboneDivision of Medical Oncology, The Ohio State University, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH.
Gregory A OttersonDivision of Medical Oncology, The Ohio State University, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH.
Carolyn J PresleyDivision of Medical Oncology, The Ohio State University, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH.
Ryan D GentzlerDivision of Hematology and Oncology, Department of Medicine, University of Virginia Cancer Center, Charlottesville, VA.
Dwight H OwenDivision of Medical Oncology, The Ohio State University, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH.

Funding

Training Hematology and Oncology Fellows in Clinical ResearchT32CA247815 · NCI · OHIO STATE UNIVERSITY · PI VERSCHRAEGEN, CLAIRE F., WESOLOWSKI, ROBERT · 2020 to 2024
$862k
NCI NIH HHS T32 CA247815
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40716972
PMCPMC13150787

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.